Wave Life Sciences Ltd. (NASDAQ:WVE) Q2 2022 Earnings Conference Call August 11, 2022 8:30 AM ET

Company Participants

Kate Rausch - Head, Investor Relations

Paul Bolno - President and Chief Executive Officer

Mike Panzara - Chief Medical Officer Head, Therapeutics Discovery and Development

Chandra Vargeese - Chief Technology Officer, Head of Platform Discovery Sciences

Kyle Moran - Chief Financial Officer

Conference Call Participants

Salim Syed - Mizuho

Luca Issi - RBC

Mary Hodge - Truist

Operator

Good morning and welcome to the Wave Life Sciences’ Second Quarter 2022 Financial Results and Business Update Conference Call. At this time, all participants are in a listen-only mode. As a reminder, this call is being recorded and webcast.

I will now turn the call over to Kate Rausch, VP of Investor Relations and Corporate Affairs at Wave Life Sciences. Please go ahead.\

Kate Rausch

Thank you, operator. Good morning and thank you for joining us today to discuss our recent business progress and review Wave's second quarter 2022 financial results.

Joining me today are Dr. Paul Bolno, President and Chief Executive Officer; Dr. Mike Panzara, Chief Medical Officer and Head of Therapeutics Discovery and Development; Dr. Chandra Vargeese, Chief Technology Officer and Head of Platform Discovery Sciences; and Kyle Moran, Chief Financial Officer.

The press release this morning and slide presentation to accompany this webcast are available in the Investors Section of our website www.wavelifesciences.com.

Before we begin, I would like to remind you that discussions during this conference call will include forward-looking statements. These statements are subject to several risks and uncertainties that could cause our actual results to differ materially from those described in the forward- looking statements. The factors that could cause actual results to differ are discussed in the press release issued today, and in our SEC filings, including our annual report on Form 10-k for the year ended December 31, 2021. And our quarterly report on Form 10-Q for the quarter ended June 30, 2022. We undertake no obligation to update or revise any forward-looking statements for any reason. And now I’d like to turn the call over to Paul. Paul?

Paul Bolno

Thanks, Kate. Good morning. And thank you all for joining us. In the second quarter, we continue to make meaningful progress both on our therapeutic program and our platform. I will start with the recent highlights. I'll then turn the call over to Mike who will provide updates on our innovative pipeline. Chandra will then share some examples of how we continue to expand the addressable biological targets with our unique RNA based editing platform. And finally, Kyle will discuss our financial.